News is everywhere. But can you trust it? How can you leverage it to gain a competitive edge? Start your free trial: Unlock expert analysis of the pharma, biotech, medtech, and consumer health with 1-week’s access to our award-winning publications.

| "The standard of care, which was really just suffering for a few extra months. was not appealing to either of us — for obvious and multiple reasons.". The Keynote from Bess Stillman at #EXTRA2025 looked the issues with access to clinical trials.

| In today’s biotech landscape, making smart, timely decisions is more critical than ever. Explore how your team can do more with less and move with confidence in a competitive market. #SmallBiotechsBigDecision

Get up to speed on pricing policy and how it could reshape global drug access: . Following Trump’s latest executive order, international reference pricing is back on the table and pharma is feeling the heat.

| In Part 3 of an interview with @PharmExec, Citeline Analyst @NehaAnand discusses how @abbvie’s antibody-drug conjugate (ADC) Emrelis is expanding treatment options for solid tumors with C-MET overexpression.

Data never looked so good! Ready to size up the latest pharma R&D trends? Our free infographic reveals how the global drug development pipeline has evolved, highlights key growth stats, and shows where the industry is headed. #RD25

| In Part 2 of an interview with @PharmExec, Citeline Analyst @NehaAnand discusses how approval of @abbvie’s antibody-drug conjugate (ADC) Emrelis signals FDA support of ADCs in oncology. #Oncology #NSCLC #Biomarkers #PrecisionMedicine

"When patients are hard to find, data helps you find them first.".Did you know that despite the growing adoption of decentralized and digital clinical trials, **85% of studies still fail to meet their recruitment targets**?.

🔥 Latest Citeline Report! Unpack 2024's unprecedented clinical trials trends from over 4,900 industry-sponsored trials! All intel powered by Trialtrove, Citeline’s top-tier research platform. Boost your strategy now at:

| Smarter clinical trials for more reliable outcomes. Gain a competitive edge with proprietary data. Download the white paper and conduct clinical trials with a competitive edge!

“Deal volume may be down—but deal value is up." Biopharma dealmakers are adapting to financial stress with smarter, more strategic transactions.

| “Organizational Challenges in Making PLS Available,” moderated by Citeline VP of Transparency Francine Lane, was a popular session at TrialScope EXTRA 2025, addressing the pain points sponsors face in creating and disseminating PLS.

| In an article in Precision Medicine Online about AstraZeneca’s Tagrisso’s Q2 success, Citeline analyst Neha Anand shares insights into growing competition in the ADC therapy market. She also notes the competitive market in HR-positive breast cancer.

| From major regulatory shifts in the EU and Japan to breakthrough drug approvals in oncology, neuroscience and cardiovascular care, 2025 is set to reshape the pharmaceutical landscape. Stay ahead with exclusive insights from our 2025 article pack.

Sign up for any Citeline product and start asking your questions today: Over 1,100 pharma professionals from around the world already trust us with some of their toughest questions.

| Country-specific sanctions and penalties are being issued for clinical trial disclosure noncompliance, warned Citeline's Thomas Wicks at TrialScope EXTRA 2025. The risk of non-compliance can be highly and extremely detrimental to a business.

What happens to drug innovation when research funding is cut? The @nytimes referenced Citeline data in its recent article on the potential impact of proposed NIH and FDA budget cuts on drug development timelines. Read the article (subscription required):

| In an interview with @PharmExec, Citeline Analyst Neha Anand discusses how AbbVie’s newly approved antibody-drug conjugate (ADC) Emrellis differentiates itself in a rapidly evolving oncology landscape.

Planning Your Clinical Strategy for 2025? Start with the data: This infographic highlights the trial trends that defined 2024 — from disease hotspots to rising sponsors. All data sourced from Trialtrove:

Finding it challenging to keep up with the intricate details of international regulatory compliance? We can help: . Dive into how Citeline Regulatory Solutions can help you save not just time but also keep you compliant around-the-clock.